ArticleFrontiers in oncology2026
The development of ovarian carcinosarcoma from serous tubal intraepithelial carcinoma: an immunohistochemical case report with literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian carcinosarcoma (OCS) is an uncommon and highly aggressive subtype of ovarian carcinoma characterized by the simultaneous occurrence of two malignant components: carcinomatous and sarcomatous. Located at the fimbrial region of the fallopian tube, serous tubal intraepithelial carcinoma (STIC) represents a form of precursor lesion for high-grade serous carcinoma (HGSC). In the current report, we present an intriguing case study of left OCS concomitant with ipsilateral STIC. Immunohistochemical (IHC) assessment showed a similar staining pattern of the carcinomatous OCS component and STIC. In conclusion, the development of OCS from STIC should be considered. Such a situation represents both a rare phenomenon and a challenge for preoperative diagnostic protocol. A careful application of selected IHC markers, p53 and Ki-67 in particular, may substantially help not only in the differential diagnosis but also in clinicopathological algorithms based on OCS molecular profiling into HGSC-like and non-HGSC-like variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.